Study examines safety and effectiveness of infliximab biosimilar in patients with inflammatory bowel disease

Biosimilars are biologic agents that highly similar to original biomedical medications (originators), but are much cheaper. A new study in Alimentary Pharmacology & Therapeutics found no differences in drug levels and disease activity between infliximab originator and an infliximab biosimilar in patients with inflammatory bowel disease, indicating that this biosimilar is indeed safe and effective.

After switching to an infliximab biosimilar, 26 percent of patients discontinued therapy within 12 months. This high rate of discontinuation was likely due to elective withdrawal or subjective disease worsening.

"Switching to biosimilars and performing therapeutic drug monitoring as part of routine care can optimize infliximab therapy of efficiently and make it more cost-effective," said senior author Dr. Luc Derijks, of the Máxima Medical Center, in The Netherlands.


Explore further

Subjective complaints may cause patients to stop treatment after switching to a biosimilar

More information: E. M. H. Schmitz et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study, Alimentary Pharmacology & Therapeutics (2017). DOI: 10.1111/apt.14453
Provided by Wiley
Citation: Study examines safety and effectiveness of infliximab biosimilar in patients with inflammatory bowel disease (2017, December 6) retrieved 5 December 2019 from https://medicalxpress.com/news/2017-12-safety-effectiveness-infliximab-biosimilar-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments